Skip to Main Content

As payers increasingly demand good value for medicines, a new analysis found that costs for dozens of cancer drugs in the U.S. were 2.3 times higher than in four wealthy European nations. And at the same time, there was generally no association between the clinical benefits of the drugs and the monthly treatment costs in most of the countries.

In other words, pricing was not aligned with the actual benefits, according to the study, which was published in The Lancet Oncology. And the findings led the researchers to conclude that existing frameworks for assessing value could not only help identify cancer medicines with small or uncertain benefits, but might also be useful tools for negotiating prices with manufacturers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!